This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Louisiana
Licensed Louisiana practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Louisiana buyers need their own professional license and NPI; the distributor license is the supplier’s obligation, not the purchaser’s.
Louisiana is unusual twice over. Distribution of legend drugs and devices is licensed by a dedicated board rather than the Board of Pharmacy, and the 2024 Hope for Louisiana Patients Law defines individualized investigational treatment to include products derived from human perinatal tissues, cells, and secreted factors, the closest any state statute other than Tennessee’s comes to exosome-adjacent language. It is worth knowing exactly what that law covers, and what it does not.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Louisiana? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | HB 899 (Act 750) (2024) |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Louisiana
ExaVeyra ships to licensed practices in all 50 states, Louisiana included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Louisiana professional license in good standing, verifiable through the Louisiana State Board of Medical Examiners LaMED portal or the Louisiana State Board of Nursing license verification service.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Louisiana resale certificate through the Department of Revenue if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Louisiana licenses distribution through a dedicated agency, the Louisiana Board of Drug and Device Distributors, rather than through the Board of Pharmacy. The Louisiana Drug and Device Distributors Act requires any person engaged in the distribution of legend drugs or legend devices to be licensed, so devices are inside the regime as in Tennessee, California, and New York. Out-of-state distributors licensed by the board keep a current copy of their home-state distribution license on file with it. The license sits with the distributor, not with the purchasing practice.
La. R.S. 37:3461 to 37:3482; La. Admin. Code tit. 46, pt. XXXIV · Louisiana Board of Drug and Device Distributors
Louisiana regenerative-medicine law
Louisiana enacted HB 899 (Act 750), codified at La. R.S. 40:1300.71 to 40:1300.80, effective 1 August 2024.
Physicians recommending, and eligible facilities and manufacturers providing, individualized investigational treatments to eligible patients: those with a life-threatening or severely debilitating illness who have considered FDA-approved options, received a physician recommendation grounded in their own genetic analysis, and given written informed consent. The facility must operate with a Federalwide Assurance for the Protection of Human Subjects. The Hope law sits alongside Louisiana’s original Right To Try Act of 2014 (R.S. 40:1300.381 to 1300.386), which covers investigational drugs, biological products, and devices for terminally ill patients. Both are access statutes with eligibility gates; neither authorizes elective regenerative services in a clinic setting.
- Individualized investigational treatments produced for a single patient, based on that patient’s own genetic profile
- Eligible patients with a life-threatening or severely debilitating illness, attested by the treating physician
- Eligible facilities operating with a Federalwide Assurance for the Protection of Human Subjects
- Written, informed consent before treatment
- Excludes products derived from embryonic stem cells or from tissues or cells derived from abortion
- Includes products derived from human perinatal tissues, cells, and secreted factors
“"Individualized investigational treatment" means drugs, biological products, or devices that are unique to and produced exclusively for use for an individual patient, based on his own genetic profile. ... "Individualized investigational treatment" does not include any drug, biological product, or device derived from human primary or secondary embryonic stem cells or cell lines, or tissues or cells derived from abortion, but does include any drug, biological product, or device derived from human perinatal tissues, cells, and secreted factors not obtained from an abortion.”
How this applies to exosomes
The Hope for Louisiana Patients Law comes closer to exosome-adjacent language than any state statute except Tennessee’s: its definition of individualized investigational treatment expressly includes products derived from human perinatal tissues, cells, and secreted factors not obtained from an abortion. It still does not name exosomes, and its reach is narrow in a way that matters. The statute is an access law for individualized treatments produced for a single patient based on that patient’s own genetic profile, available to eligible patients at facilities operating under a Federalwide Assurance. A manufactured exosome product supplied to a clinic is not individualized to one patient’s genome, so the statute does not reach acellular extracellular vesicles as a product class, either to permit or to restrict them. Exosome products in Louisiana remain governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Louisiana practice
Louisiana splits oversight across more agencies than most states: the Louisiana State Board of Medical Examiners for physicians and physician assistants, the Louisiana State Board of Nursing for RNs and APRNs, and a dedicated Board of Drug and Device Distributors on the supply side. For most practices the operating assumption is a collaborative practice agreement between any APRN and a physician, with the statutory exemption for experienced APRNs confirmed case by case with the nursing board.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Louisiana State Board of Medical Examiners may perform medical acts within their scope and are the source of any delegation to staff who do not hold independent authority. |
| NP / APRN | Louisiana advanced practice registered nurses practice under a collaborative practice agreement with one or more physicians or dentists under R.S. 37:913, covering availability of the collaborating physician, clinical practice guidelines, and coverage during absences. Statute also provides an exemption pathway from the agreement for APRNs meeting experience qualifications, so confirm an individual APRN’s status with the Louisiana State Board of Nursing. |
| PA | Physician assistants are licensed by the Louisiana State Board of Medical Examiners and practice in the scope their supervising or collaborating physician establishes under the board’s rules. |
| RN | Registered nurses may perform delegated treatments within their scope under the Louisiana State Board of Nursing’s rules, under an order from a provider with authority to issue one and after that provider has evaluated the patient. An RN does not diagnose, prescribe, or independently select a treatment. |
Good faith examination
Louisiana expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. For an APRN the evaluation and order run through the collaborative practice agreement or a confirmed statutory exemption. Confirm current expectations with the Louisiana State Board of Medical Examiners and the Louisiana State Board of Nursing.
Ownership and clinic licensing
Louisiana does not codify a corporate practice of medicine prohibition of the Texas or New York kind, and physician employment by non-physician entities is common. Professional corporations and management services arrangements remain the usual structures for aesthetic practices, and the Louisiana State Board of Medical Examiners still expects medical decisions to sit with licensed clinicians. Structure ownership with Louisiana counsel rather than from a summary.
Cold chain into Louisiana
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Louisiana order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| New Orleans | Orleans Parish | Largest Louisiana market, with deep aesthetic and dermatology coverage. |
| Metairie | Jefferson Parish | Dense suburban med spa corridor served alongside New Orleans. |
| Baton Rouge | East Baton Rouge Parish | Capital market with a broad clinical base. |
| Lafayette | Lafayette Parish | Acadiana hub with a growing aesthetic segment. |
| Shreveport | Caddo Parish | Northwest Louisiana market with academic medical presence. |
| Covington | St. Tammany Parish | Northshore market with concierge and wellness practices. |
- Louisiana orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Every vial arrives with the manufacturer’s handling instructions and a Certificate of Analysis, and storage on arrival follows the COA and labeling rather than a general rule.
Wholesale exosome supply by city in Louisiana
Each city page covers local receiving conditions, delivery disruptions and business license rules for Louisiana practices in that area.
Practice types we supply in Louisiana
Louisiana licensing and verification
Louisiana State Board of Medical Examiners
Physicians and physician assistants; license verification through the LaMED portal.
Louisiana State Board of Nursing
RNs and APRNs, including collaborative practice agreement status.
Louisiana Board of Drug and Device Distributors
The dedicated board that licenses legend drug and device distributors shipping into Louisiana. The board’s own site was unreachable when this page was reviewed, so the link points at its enabling act on the legislature’s site.
Louisiana Board of Pharmacy
Pharmacies and pharmacists; distribution licensing sits with the separate distributors board.
Louisiana Department of Revenue
Sales tax registration and resale certificates.
Louisiana sourcing questions
- Does Louisiana have a stem cell law?
- Not a clinic authorization law like Florida, Texas, or Georgia. Louisiana has two access statutes instead: the Right To Try Act of 2014 for terminally ill patients, and the Hope for Louisiana Patients Law of 2024 for individualized investigational treatments. Both carry eligibility gates, and neither authorizes elective regenerative services in a clinic setting. Exosome products in Louisiana are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- What does the Hope for Louisiana Patients Law actually cover?
- Individualized investigational treatments: drugs, biological products, or devices produced exclusively for one patient based on that patient’s own genetic profile, provided to eligible patients with a life-threatening or severely debilitating illness at facilities operating under a Federalwide Assurance. Its definition expressly includes products derived from human perinatal tissues, cells, and secreted factors not obtained from an abortion, and excludes products derived from embryonic stem cells or from abortion. A manufactured product supplied to a clinic is not individualized to one genome, so the law does not reach exosome products as a class.
- Who licenses wholesale distribution into Louisiana?
- The Louisiana Board of Drug and Device Distributors, a dedicated board separate from the Board of Pharmacy, under the Louisiana Drug and Device Distributors Act, R.S. 37:3461 and following. The regime covers legend devices as well as legend drugs, and the license sits with the distributor shipping in, not with the practice buying.
- Does my Louisiana clinic need a distributor license to buy exosomes?
- No. The distributor license under R.S. 37:3461 is held by the entity shipping into Louisiana, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Can a nurse practitioner practice without a physician in Louisiana?
- The default is no: Louisiana APRNs practice under a collaborative practice agreement with one or more physicians or dentists under R.S. 37:913. Statute also provides an exemption pathway for APRNs who meet experience qualifications, so some APRNs practice without an agreement. Confirm an individual APRN’s status with the Louisiana State Board of Nursing before building a practice structure around it.
- Are exosome products FDA approved?
- No exosome product has been approved by the FDA for administration to humans, a position the FDA stated in its 2019 public safety notification on exosome products. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to Louisiana?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- La. R.S. 37:3461, Louisiana Drug and Device Distributors Act, general provisions and short title (accessed 16 October 2026)
- La. R.S. 40:1300.71, Hope for Louisiana Patients Law, short title (accessed 16 October 2026)
- La. R.S. 40:1300.72, Hope for Louisiana Patients Law, definitions (accessed 16 October 2026)
- La. R.S. 37:913, advanced practice registered nursing definitions and collaborative practice (accessed 16 October 2026)
- Louisiana State Board of Medical Examiners (accessed 16 October 2026)
- Louisiana State Board of Nursing (accessed 16 October 2026)
- Louisiana Department of Revenue (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Consensus statementsupports: Supports the documentation standard this page describes: the field-consensus characterization measures, including particle counts and marker panels, that a COA-literate buyer looks for on an exosome Certificate of Analysis.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Consensus statementsupports: Supports the page’s core distinction that exosomes are acellular extracellular vesicles, defined and characterized separately from the cells and tissues that state statutes are written around.
- Kou M, Huang L, Yang J, et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool?. Cell Death and Disease, 2022. doi:10.1038/s41419-022-05034-x PMID:35787632Narrative reviewsupports: Supports the page’s description of MSC-derived extracellular vesicles, including perinatal MSC-EV preparations, as secreted-factor source material whose characterization and provenance a purchasing practice documents.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.